GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.
Beam Therapeutics, a US-based genetic medicine spinout of Harvard University, closed a $135m series B round yesterday that included GV, the subsidiary of internet and technology group Alphabet formerly known as Google Ventures.
F-Prime Capital and Eight Roads Ventures, subsidiaries of investment and financial services group Fidelity, also took part in the round, as did Redmile Group, Omega Funds, Cormorant Asset Management, Altitude Life Science Ventures and Arch Venture Partners.
Founded in 2017, Beam is using base editing…
